Lance Baldo stepped down as chief medical officer of Adaptive Biotechnologies. Baldo is “moving on to pursue another professional opportunity in the early cancer screening market close to home,” a spokesperson for the Seattle company told GeekWire. The physician and former head of U.S. medical affairs at Genentech has been based out of South San Francisco and joined publicly traded Adaptive in 2019.
The move comes after Adaptive laid off 12% of its workforce, about 100 employees, in early March. The company also announced a new CFO, Tycho Peterson, and narrowed its focus to two key business areas, immune medicine and detection of minimal residual disease (MRD) in oncology.
The medical team now reports to Sharon Benzeno, chief commercial officer for immune medicine, and Nitin Sood, chief commercial officer for MRD. Benzeno was previously a company-wide chief business development officer and Sood was chief commercial officer.
